Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue ReadingAllogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth…

Continue ReadingAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia